18:56 , Oct 27, 2017 |  BC Week In Review  |  Clinical News

Biogen reports Phase IIa data for IPF candidate

In its 3Q17 earnings presentation, Biogen Inc. (NASDAQ:BIIB) said BG00011 (STX-100) achieved "proof of biology" in a Phase IIa trial by showing "substantial" downregulation of the transforming growth factor (TGF) beta pathway as measured by...
07:00 , Oct 13, 2014 |  BioCentury  |  Regulation

The lung haul

Patients at FDA's recent workshop on idiopathic pulmonary fibrosis said they want treatments that can halt or reverse the progression of fibrosis and - just as importantly - improve quality of life. But they will...
07:00 , Oct 13, 2014 |  BioCentury  |  Regulation

The lung haul

Patients at FDA's recent workshop on idiopathic pulmonary fibrosis said they want treatments that can halt or reverse the progression of fibrosis and - just as importantly - improve quality of life. But they will...
07:00 , Sep 8, 2014 |  BioCentury  |  Strategy

Parsing Roche's IPF bet

InterMune Inc.'s third Phase III trial transformed it from a forgotten company with $70.3 million in 2013 sales of one Orphan product to a takeout play worth $8.3 billion to Roche. The question now is...
07:00 , Jul 31, 2014 |  BC Innovations  |  Cover Story

Fresh air for COPD

An undisclosed company has picked up an integrin-targeting antibody from the University of California, San Francisco that could address the underlying pathology in chronic obstructive pulmonary disease by improving airway remodeling via suppressing transforming growth...
08:00 , Dec 5, 2013 |  BC Innovations  |  Cover Story

Targeting fibrotic integrin

Fibrosis has long been associated with the activation of transforming growth factor-b by integrin, but the mechanism underlying the process in vivo was not known. Now, an international team has shown that the myofibroblast-expressed integrin...
07:00 , Jul 30, 2012 |  BC Week In Review  |  Clinical News

STX-100: Phase IIa started

Biogen Idec disclosed in its 2Q12 earnings that in July it began a double-blind, placebo-controlled, U.S. Phase IIa trial to evaluate weekly subcutaneous STX-100 for 8 weeks in 32 IPF patients. The trial includes 4...
07:00 , Mar 15, 2012 |  BC Innovations  |  Targets & Mechanisms

Halofuginone target ID

A U.S. and South Korean research team has identified the molecular target of halofuginone, a small molecule antifibrotic and anti-inflammatory compound.1 The findings could help guide the design of next-generation halofuginone analogs with improved pharmacological...
08:00 , Feb 20, 2012 |  BioCentury  |  Strategy

Biogen buys back in

Biogen Idec Inc. is buying Stromedix Inc. to re-acquire the anti-fibrotic mAb it cast off five years ago. The big biotech thinks the time is ripe because FDA has clarified a regulatory path in idiopathic...
08:00 , Feb 20, 2012 |  BC Week In Review  |  Company News

Biogen Idec, Stromedix deal

Biogen Idec will acquire Stromedix for $75 million up front, and up to $487.5 million in milestones. Stromedix is developing STX-100, a humanized mAb against integrin alpha(V)beta(6), to treat fibrotic disease. The product...